Rosiglitazone Toxicity

Letters17 October 2000Rosiglitazone ToxicityRavi Sudhir Ravinuthala, MD, MRCP and Uday Nori, MDRavi Sudhir Ravinuthala, MD, MRCPHenry Ford Hospital; Detroit, MI 48202 (Sudhir, Ravinuthala, Nori) and Uday Nori, MDHenry Ford Hospital; Detroit, MI 48202 (Sudhir, Ravinuthala, Nori)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-8-200010170-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest the two case reports by Forman and colleagues (1) and Al-Salman and colleagues (2) describing possible hepatocellular injury associated with rosiglitazone. We report our experience of rosiglitazone-related hepatic injury.A 58-year-old woman with long-standing diabetes was taking glyburide, lisinopril, and hydrochlorothiazide; the doses had remained the same for at least 1 year. Two weeks after rosiglitazone (4 mg/d) was added to her regimen, she felt ill. She was admitted to the hospital 1 week later. Results of baseline liver function tests before therapy with the drug began were normal. The patient was icteric ...References1. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-21. LinkGoogle Scholar2. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 2000;132:121-4. LinkGoogle Scholar3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Ravi Sudhir Ravinuthala, MD, MRCP; Uday Nori, MDAffiliations: Henry Ford Hospital; Detroit, MI 48202 (Sudhir, Ravinuthala, Nori) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHepatic Failure in a Patient Taking Rosiglitazone Lisa M. Forman , David A. Simmons , and Robert H. Diamond Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report Jameela Al-Salman , Heider Arjomand , David G. Kemp , and Manoj Mittal Hepatocellular Injury in a Patient Receiving Pioglitazone Kenji Maeda Did This Drug Cause My Patient's Hepatitis? Neil Kaplowitz , James H. Lewis , and Paul B. Watkins Metrics Cited byPioglitazone Increases Blood–Brain Barrier Expression of Fatty Acid-Binding Protein 5 and Docosahexaenoic Acid Trafficking into the BrainVSP-17, a New PPARγ Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-CadherinThiazolidinedionesEffect of Rosiglitazone on Liver Structure and Function in Genetically Diabetic Akita MiceThe safety of thiazolidinedionesImportant Elements for the Diagnosis of Drug-Induced Liver InjuryInsulin releasing and alpha-glucosidase inhibitory activity of ethyl acetate fraction of Acorus calamus in vitro and in vivoCase series of liver failure associated with rosiglitazone and pioglitazoneINSULINS AND OTHER HYPOGLYCEMIC DRUGSThe Glitazones, Lessons so FarThiazolidinedionesReview article: the treatment of non-alcoholic steatohepatitis with thiazolidinedionesSecond-Generation Thiazolidinediones and HepatotoxicityHepatotoxicity of thiazolidinedionesHepatotoxicity of the thiazolidinedionesDid This Drug Cause My Patient's Hepatitis?Neil Kaplowitz, MD, James H. Lewis, MD, and Paul B. Watkins, MDCounseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient SettingEditor's MailboxThiazolidinediones and type 2 diabetes: new drugs for an old diseaseEffects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical recordsInsulin, glucagon, and hypoglycemic drugsRosiglitazoneHepatocellular Injury in a Patient Receiving PioglitazoneKenji Maeda, MDDrug-induced liver diseaseRosiglitazoneCurrent AwarenessNeue Arzneimittel 17 October 2000Volume 133, Issue 8Page: 658KeywordsAdverse reactionsAlanine aminotransferaseDrug therapyHospitalizationsInformation storage and retrievalLiverLiver function testsSerum glutamic oxaloacetic transaminaseToxicityUltrasound imaging ePublished: 17 October 2000 Issue Published: 17 October 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...